Institutional review board

BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, September 2, 2023

Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 5, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.
  • The Company announced that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III.
  • BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.

BIOXCEL 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

Retrieved on: 
Saturday, September 2, 2023

This action is pending in the United States District Court for the District of Connecticut.

Key Points: 
  • This action is pending in the United States District Court for the District of Connecticut.
  • BioXcel and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • The case is Martin v. BioXcel Therapeutics, Inc., et al., No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

Retrieved on: 
Friday, September 1, 2023

On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.

Key Points: 
  • On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease.
  • The Company announced that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III.
  • BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc.(BTAI) Shareholders

Retrieved on: 
Thursday, August 31, 2023

NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.

Key Points: 
  • NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.
  • WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in BioXcel you have until September 5, 2023 to petition the court for lead plaintiff status.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
  • HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the BTAI lawsuit, please contact J. Klein, Esq.

DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, August 31, 2023

BENSALEM, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)

Retrieved on: 
Wednesday, August 30, 2023

Appointment as lead plaintiff is not required to partake in any recovery.

Key Points: 
  • Appointment as lead plaintiff is not required to partake in any recovery.
  • DEADLINE: September 5, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is September 5, 2023.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

Retrieved on: 
Wednesday, August 30, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

Retrieved on: 
Tuesday, August 29, 2023

If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.

Key Points: 
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

EmVenio Research expands clinical research team to streamline efficiency and compliance processes

Retrieved on: 
Monday, August 28, 2023

DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes. Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training. Their hiring aligns with EmVenio's goal to ensure that the clinical trial team conducts and will maintain adherence to the latest Federal Drug Administration regulations and in accordance with Good Clinical Practice and International Conference of Harmonization guidelines.

Key Points: 
  • DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes.
  • Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training.
  • EmVenio Research appointed Christine Scheuring and Vickie Leathers to manage its clinical research teams and processes.
  • "Adding Christine and Vickie reinforces our research team's effort to remain on the forefront of developments in the clinical research realm."

BTAI 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys Before Sept. 5th Deadline in Securities Fraud Class Action

Retrieved on: 
Monday, August 28, 2023

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .
  • BioXcel Therapeutics, Inc. (BTAI) Securities Fraud Class Action:
    The litigation focuses on BioXcel’s statements and omissions regarding its TRANQUILITY II study evaluating its Alzheimer candidate drug BXCL501.
  • If you invested in BioXcel and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding BioXcel Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.